David Jensen
General Practice · Palmdale, CANPI 1093731325
Payments from drug & device makers
Across 365 payments — averaging $18.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Novo Nordisk$761
- AstraZeneca$618
- Lilly USA, LLC$585
- GSK$492
- Merck$403
- plus $3K from 32 others
What the payments were for
- Food & beverage$6,667100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 70 | $1,232 |
| Novo Nordisk | 51 | $761 |
| AstraZeneca | 34 | $618 |
| Lilly USA, LLC | 32 | $585 |
| GSK | 28 | $492 |
| Merck | 19 | $403 |
| Boehringer Ingelheim | 15 | $298 |
| Amarin Pharma, Inc. | 14 | $267 |
| Novartis | 15 | $262 |
| Pfizer | 12 | $219 |
| AbbVie(2 entities) | 8 | $199 |
| Otsuka America Pharmaceutical, Inc. | 11 | $185 |
| Lundbeck LLC | 9 | $182 |
| Biohaven Pharmaceuticals, Inc. | 7 | $141 |
| Nestle Healthcare Nutrition Inc. | 4 | $91 |
| Dexcom, Inc. | 5 | $89 |
| Johnson & Johnson | 3 | $77 |
| Vanda Pharmaceuticals Inc. | 3 | $76 |
| Esperion Therapeutics, Inc. | 3 | $61 |
| Scilex Pharmaceuticals Inc. | 2 | $39 |
| Alkermes, Inc. | 2 | $39 |
| Eisai Inc. | 2 | $37 |
| Stryker | 1 | $29 |
| Aimmune Therapeutics, Inc. | 1 | $25 |
| Phathom Pharmaceuticals, Inc. | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Optinose US, Inc. | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Acerus Pharmaceuticals Corporation | 1 | $21 |
| Evoke Pharma, Inc. | 1 | $20 |
| Vertiflex, Inc. | 1 | $20 |
| Clarus Therapeutics Inc. | 1 | $20 |
| Irhythm Technologies, Inc. | 1 | $17 |
| Boston Scientific | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$6,673 in reported general payments places this provider in the 95th percentile of 12,963 general practice providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 153 | $203,012 |
| RybelsusSemaglutide | 62 | $104,316 |
| Repatha SureclickEvolocumab | 83 | $61,771 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 25 | $58,145 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $54,529 |
| KerendiaFinerenone | 39 | $53,922 |
| MounjaroTirzepatide | 29 | $29,334 |
| EntrestoSacubitril/Valsartan | 22 | $28,116 |
| ProliaDenosumab | 15 | $24,228 |
| EliquisApixaban | 23 | $21,138 |
| JanuviaSitagliptin Phosphate | 12 | $18,980 |
| OzempicSemaglutide | 19 | $18,116 |
| XareltoRivaroxaban | 14 | $15,327 |
| Repatha SyringeEvolocumab | 22 | $12,185 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $11,050 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $298 | $203,012153 claims |
| Novo NordiskRybelsus, Ozempic | $761 | $122,43181 claims |
| AmgenEvenity (2 Syringes), Prolia | $1,232 | $82,37340 claims |
| GSKTrelegy Ellipta | $492 | $54,52950 claims |
| Lilly USA, LLCMounjaro | $585 | $29,33429 claims |
| NovartisEntresto | $262 | $28,11622 claims |
| PfizerEliquis | $219 | $21,13823 claims |
| MerckJanuvia | $403 | $18,98012 claims |
| Johnson & JohnsonXarelto | $77 | $15,32714 claims |
| AstraZenecaBreztri Aerosphere | $618 | $11,05018 claims |
| AbbVieLinzess | $199 | $8,63812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 12,963 general practice providers in California.
Other general practice in Palmdale
- Hessam AazamiCanoga Park$88.4M
- Frederic MollRedwood City$5.7M
- Nathan LiLancaster$5.2M
- Milton McCollSan Jose$4.9M
- Bruce TorkanLos Angeles$3.8M
- Daniel JohnsonPalm Desert$1.5M
- Bradley ChingUpland$1.4M
- Jared AdamsSan Francisco$862K
- Marina GoldGlendale$784K
- Eric BrassTorrance$755K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.